Skip to main content
NCBI home page
British Heart Journal logoLink to British Heart Journal
. 1983 Sep;50(3):277–281. doi: 10.1136/hrt.50.3.277

Metabolic and haemodynamic effects of increased circulating adrenaline in man. Effect of labetalol, an alpha and beta blocker.

A D Struthers, R Whitesmith, J L Reid
PMCID: PMC481409  PMID: 6615664

Abstract

To simulate increased sympathoadrenal activity adrenaline was infused in normotensive subjects to achieve plasma adrenaline concentrations similar to those seen after myocardial infarction or hypoglycaemia. Adrenaline was infused after pretreatment for five days with labetalol 200 mg twice daily or placebo given in a random order. The rise in systolic blood pressure and the fall in diastolic blood pressure observed after the infusion of adrenaline (0.06 micrograms/kg/min) were prevented by labetalol and no increase in blood pressure was seen. Adrenaline infusion after pretreatment with placebo caused a profound fall in the serum potassium concentration (4.12-3.20 mmol(mEq)/l). Pretreatment with labetalol completely blocked adrenaline induced hypokalaemia (3.92-3.95 mmol(mEq)/l). Adrenaline induced T wave flattening and QTc prolongation were also prevented by labetalol. Thus labetalol can prevent the electrocardiographic, haemodynamic, and hypokalaemic effects of increased circulating adrenaline in man. The combination of alpha and beta blockade appears to be required to block the haemodynamic effects of adrenaline, and labetalol may, therefore, be useful in controlling both the metabolic and circulatory responses during increased sympathoadrenal activity.

Full text

PDF
277

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Clausen T., Flatman J. A. Beta 2-adrenoceptors mediate the stimulating effect of adrenaline on active electrogenic Na-K-transport in rat soleus muscle. Br J Pharmacol. 1980 Apr;68(4):749–755. doi: 10.1111/j.1476-5381.1980.tb10868.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Cryer P. E. Physiology and pathophysiology of the human sympathoadrenal neuroendocrine system. N Engl J Med. 1980 Aug 21;303(8):436–444. doi: 10.1056/NEJM198008213030806. [DOI] [PubMed] [Google Scholar]
  3. Hjalmarson A., Elmfeldt D., Herlitz J., Holmberg S., Málek I., Nyberg G., Rydén L., Swedberg K., Vedin A., Waagstein F. Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial. Lancet. 1981 Oct 17;2(8251):823–827. doi: 10.1016/s0140-6736(81)91101-6. [DOI] [PubMed] [Google Scholar]
  4. Levene D. L., Freeman M. R. Alpha-adrenoceptor-mediated coronary artery spasm. JAMA. 1976 Aug 30;236(9):1018–1022. [PubMed] [Google Scholar]
  5. Mason D. T. Afterload reduction and cardiac performance. Physiologic basis of systemic vasodilators as a new approach in treatment of congestive heart failure. Am J Med. 1978 Jul;65(1):106–125. doi: 10.1016/0002-9343(78)90700-3. [DOI] [PubMed] [Google Scholar]
  6. Massara F., Tripodina A., Rotunno M. Propranolol block of epinephrine-induced hypokaliaemia in man. Eur J Pharmacol. 1970;10(3):404–407. doi: 10.1016/0014-2999(70)90214-1. [DOI] [PubMed] [Google Scholar]
  7. Med M. Prenatal development of lumbar intervertebral articulation. Folia Morphol (Praha) 1982;30(3):285–290. [PubMed] [Google Scholar]
  8. Peter T., Norris R. M., Clarke E. D., Heng M. K., Singh B. N., Williams B., Howell D. R., Ambler P. K. Reduction of enzyme levels by propranolol after acute myocardial infarction. Circulation. 1978 Jun;57(6):1091–1095. doi: 10.1161/01.cir.57.6.1091. [DOI] [PubMed] [Google Scholar]
  9. Ricci D. R., Orlick A. E., Cipriano P. R., Guthaner D. F., Harrison D. C. Altered adrenergic activity in coronary arterial spasm: insight into mechanism based on study of coronary hemodynamics and the electrocardiogram. Am J Cardiol. 1979 Jun;43(6):1073–1079. doi: 10.1016/0002-9149(79)90137-1. [DOI] [PubMed] [Google Scholar]
  10. Richards D. A., Prichard B. N. Clinical pharmacology of labetalol. Br J Clin Pharmacol. 1979;8(Suppl 2):89S–93S. [PMC free article] [PubMed] [Google Scholar]
  11. Richards D. A., Prichard B. N., Hernández R. Circulatory effects of noradrenaline and adrenaline before and after labetalol. Br J Clin Pharmacol. 1979 Apr;7(4):371–378. [PMC free article] [PubMed] [Google Scholar]
  12. Rizza R. A., Cryer P. E., Gerich J. E. Role of glucagon, catecholamines, and growth hormone in human glucose counterregulation. Effects of somatostatin and combined alpha- and beta-adrenergic blockade on plasma glucose recovery and glucose flux rates after insulin-induced hypoglycemia. J Clin Invest. 1979 Jul;64(1):62–71. doi: 10.1172/JCI109464. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Struthers A. D., Reid J. L., Whitesmith R., Rodger J. C. Effect of intravenous adrenaline on electrocardiogram, blood pressure, and serum potassium. Br Heart J. 1983 Jan;49(1):90–93. doi: 10.1136/hrt.49.1.90. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Struthers A. D., Reid J. L., Whitesmith R., Rodger J. C. The effects of cardioselective and non-selective beta-adrenoceptor blockade on the hypokalaemic and cardiovascular responses to adrenomedullary hormones in man. Clin Sci (Lond) 1983 Aug;65(2):143–147. doi: 10.1042/cs0650143. [DOI] [PubMed] [Google Scholar]
  15. Taylor S. H., Silke B., Nelson G. I., Okoli R. C., Ahuja R. C. Haemodynamic advantages of combined alpha-blockade and beta-blockade over beta-blockade alone in patients with coronary heart disease. Br Med J (Clin Res Ed) 1982 Jul 31;285(6338):325–327. doi: 10.1136/bmj.285.6338.325. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Yusuf S., Ramsdale D., Peto R., Furse L., Bennett D., Bray C., Sleight P. Early intravenous atenolol treatment in suspected acute myocardial infarction. Preliminary report of a randomised trial. Lancet. 1980 Aug 9;2(8189):273–276. doi: 10.1016/s0140-6736(80)90231-7. [DOI] [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES